

## CADTH DRUG REIMBURSEMENT REVIEW

# Pharmacoeconomic Report

## BRIGATINIB (ALUNBRIG)

(Takeda Canada Inc.)

**Indication:** For the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) previously untreated with an ALK inhibitor.

**Disclaimer:** The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada's federal, provincial, or territorial governments or any third-party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian *Copyright Act* and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

**About CADTH:** CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

**Funding:** CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

## Table of Contents

List of Tables .....	4
Abbreviations .....	5
Executive Summary .....	6
Conclusions .....	8
Stakeholder Input Relevant to the Economic Review .....	9
Economic Review .....	10
Appendix 1: Cost Comparison Table .....	11
Appendix 2: Submission Quality .....	12
Appendix 3: Additional Information on the Submitted Economic Evaluation .....	13
Appendix 4: Additional Details on the CADTH Reanalyses and Sensitivity Analyses of the Economic Evaluation .....	14
Appendix 5: Submitted BIA and CADTH Appraisal .....	15

## List of Tables

Table 1: Submitted for Review.....	6
Table 2: Summary of Economic Evaluation.....	7

## Abbreviations

AIC	Akaike Information Criterion
ALK	anaplastic lymphoma kinase
BIC	Bayesian Information Criterion
BIRC	blinded independent review committee
DoT	Duration on treatment
ICER	incremental cost-effectiveness ratio
ITC	indirect treatment comparison
LY	life-year
MAIC	matched-adjusted indirect comparison
NSCLC	non-small cell lung cancer
OS	overall survival
pCODR	pan-Canadian Oncology Drug Review
PERC	pCODR Expert Review Committee
PFS	progression-free survival
QALY	quality-adjusted life-year
RECIST	Response Evaluation Criteria in Solid Tumors

## Executive Summary

The executive summary is comprised of two tables (Table 1: Background and Table 2: Economic Evaluation) and a conclusion.

**Table 1: Submitted for Review**

Item	Description
Drug product	brigatinib (Alunbrig), oral tablets
Submitted price	brigatinib, 30 mg: \$112.32 per tablet brigatinib, 90 mg and 180 mg: \$336.96 per tablet
Indication	For the first line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC)
Health Canada approval status	Approved
Health Canada review pathway	Standard
NOC date	March 3, 2021
Reimbursement request	Adult patients with ALK-positive locally advanced (not amenable to curative therapy) or metastatic NSCLC previously untreated with an ALK inhibitor
Sponsor	Takeda Canada Inc.
Submission history	Previously reviewed: Yes Indication: adult patients with ALK-positive metastatic NSCLC who have progressed on or who were intolerant to an ALK inhibitor (crizotinib) Recommendation date: August 1, 2019 Recommendation: Do not reimburse

ALK = anaplastic lymphoma kinase; NOC = Notice of Compliance; NSCLC = non-small cell lung cancer

**Table 2: Summary of Economic Evaluation**

Component	Description
<b>Type of economic evaluation</b>	Cost-utility analysis Partitioned survival model
<b>Target population</b>	Adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) previously untreated with an ALK inhibitor (per the reimbursement request)
<b>Treatment</b>	Brigatinib
<b>Comparators</b>	<ul style="list-style-type: none"> <li>• Crizotinib</li> <li>• Alectinib</li> </ul>
<b>Perspective</b>	Canadian publicly funded health care payer
<b>Outcome</b>	QALYs, LYs
<b>Time horizon</b>	Lifetime (30 years)
<b>Key data sources</b>	<ul style="list-style-type: none"> <li>• ALTA-1L trial – brigatinib vs crizotinib</li> <li>• Unanchored matched-adjusted indirect comparison (MAIC; ALTA-1L trial, ALEX trial, ASCEND-4 trial) – brigatinib vs alectinib (crizotinib was not included in the analysis)</li> </ul>
<b>Submitted results for base case</b>	<ul style="list-style-type: none"> <li>• Brigatinib was more costly and produced more QALYs than alectinib and crizotinib</li> <li>• Incremental cost-effectiveness ratio (ICER) for brigatinib vs. crizotinib was \$113,007 per QALY (inc. cost: 126,266; incr. QALYs: 1.12)</li> <li>• Alectinib was extendedly dominated through crizotinib and brigatinib<sup>a</sup></li> </ul>
<b>Key limitations</b>	<ul style="list-style-type: none"> <li>• The sponsor’s base case assumed Duration on Treatment (DoT) was equal to progression-free survival (PFS) for each treatment. Trial-observed DoT for each comparator and feedback from clinical experts consulted by CADTH indicated that PFS underestimates DoT.</li> <li>• The sponsor incorporated treatment-specific utilities, which does not reflect CADTH guidelines.</li> <li>• The CADTH Clinical Review identified several limitations with the sponsor’s unanchored MAIC between brigatinib and alectinib. The clinical review concluded that internal validity of the results of the sponsor’s unanchored MAIC was low quality. CADTH attempted to address the uncertainty in the comparative efficacy data by applying the comparative estimates from a sponsor’s results must be interpreted with caution and recommended the use of a published network meta-analysis (NMA) that included comparisons between brigatinib versus alectinib and brigatinib versus crizotinib instead. While the estimates from this source were considered more appropriate due to the use of established methods and rigorous reporting, the CADTH Clinical Review noted that limitations remain, and results should be interpreted with caution.</li> </ul>
<b>CADTH reanalysis results</b>	<ul style="list-style-type: none"> <li>• CADTH reanalyses included: the revision of data used to inform how DoT was modeled for brigatinib and crizotinib; the application of alternate literature estimates for each health state’s utility weights; and, the use of a published NMA’s hazard ratios to characterize overall survival and PFS between brigatinib and alectinib. CADTH was unable to address potential uncertainty in the extrapolation of OS for crizotinib.</li> <li>• CADTH found: <ul style="list-style-type: none"> <li>○ Brigatinib was dominated by alectinib (brigatinib is more costly, less effective)</li> <li>○ Alectinib vs. crizotinib: ICER = \$56,986 per QALY</li> <li>○ At a WTP threshold of \$50,000 per QALY, brigatinib had a 0% chance of being cost-effective compared to alectinib. A price reduction of at least 46% would be required for total costs associated with brigatinib to be those of alectinib.</li> </ul> </li> </ul>

ALK = anaplastic lymphoma kinase; DoT = duration on treatment; incr. = incremental; ICER = incremental cost-effectiveness ratio; LY = life-year; NMA = network meta-analysis; NSCLC = non-small cell lung cancer; PSM = partitioned survival model; QALY= quality-adjusted life-year; vs. = versus; inc. = incremental; WTP = willingness to pay

<sup>a</sup> Treatment has a higher ICER when compared to the next more effective treatment

## Conclusions

The ALTA-1L study reported that, in adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) previously untreated with an ALK inhibitor, the difference in progression-free survival was statistically significant between brigatinib and crizotinib. However, overall survival was immature in both comparators and the net survival benefit observed for brigatinib compared with crizotinib was not statistically significant during the course of the trial (two years). The assumed and extrapolated difference in mortality between these comparators is a key driver in the economic analysis.

CADTH undertook reanalyses to address limitations relating to data on treatment duration used to inform model parameters; the type of the utility weights applied to each health state; and, the hazard ratios characterizing overall survival and progression-free survival between brigatinib and alectinib. Based on the CADTH sequential analysis, brigatinib was dominated (more costly, less effective) by alectinib. The probability that brigatinib was cost-effective compared to alectinib at a willingness-to-pay threshold of \$50,000 per QALY gained was 0%. No price reduction analysis was conducted, as the base case suggested that brigatinib produced fewer QALYs than alectinib.

CADTH's Clinical Review found that results from a published NMA were more methodologically rigorous than the sponsor's submitted unanchored MAIC for estimating relative treatment effect. However, in addition to notable parameter uncertainty in OS and PFS curves within the NMA, the CADTH Clinical Review also noted methodological limitations within the NMA that contribute additional uncertainty to the estimates of the hazard ratios. Additionally, the lack of data for time on treatment for alectinib resulted in the CADTH estimate of incremental cost of brigatinib (compared to alectinib) being disproportionately high. These limitations suggest that CADTH's assessment of the cost-effectiveness of brigatinib is associated with uncertainty.

Based on the sponsor's submitted budget impact analysis, introducing brigatinib was associated with an estimated budget-impact of ████████ over the first three years. CADTH re-analyses estimated a budget impact of \$8,878,577 (\$1,491,797 in year 1, \$3,155,075 in year 2, \$4,231,705 in year 3).



## Stakeholder Input Relevant to the Economic Review

This section outlines the technical details of the pCODR Economic Guidance Panel's evaluation of the economic evidence that is summarized in the executive summary. In accordance with the *Disclosure of Information Guidelines for the CADTH Pan-Canadian Oncology Drug Review*, this section is not eligible for disclosure. It was provided to the pCODR Expert Review Committee (pERC) for their deliberations and the participating drug programs for their information.

## Economic Review

This section outlines the technical details of the pCODR Economic Guidance Panel's evaluation of the economic evidence that is summarized in the executive summary. In accordance with the *Disclosure of Information Guidelines for the CADTH Pan-Canadian Oncology Drug Review*, this section is not eligible for disclosure. It was provided to the pCODR Expert Review Committee (pERC) for their deliberations and the participating drug programs for their information.

## Appendix 1: Cost Comparison Table

This section outlines the technical details of the pCODR Economic Guidance Panel's evaluation of the economic evidence that is summarized in the executive summary. In accordance with the *Disclosure of Information Guidelines for the CADTH Pan-Canadian Oncology Drug Review*, this section is not eligible for disclosure. It was provided to the pCODR Expert Review Committee (pERC) for their deliberations and the participating drug programs for their information.

## Appendix 2: Submission Quality

This section outlines the technical details of the pCODR Economic Guidance Panel's evaluation of the economic evidence that is summarized in the executive summary. In accordance with the *Disclosure of Information Guidelines for the CADTH Pan-Canadian Oncology Drug Review*, this section is not eligible for disclosure. It was provided to the pCODR Expert Review Committee (pERC) for their deliberations and the participating drug programs for their information.

## **Appendix 3: Additional Information on the Submitted Economic Evaluation**

This section outlines the technical details of the pCODR Economic Guidance Panel's evaluation of the economic evidence that is summarized in the executive summary. In accordance with the *Disclosure of Information Guidelines for the CADTH Pan-Canadian Oncology Drug Review*, this section is not eligible for disclosure. It was provided to the pCODR Expert Review Committee (pERC) for their deliberations and the participating drug programs for their information.

## **Appendix 4: Additional Details on the CADTH Reanalyses and Sensitivity Analyses of the Economic Evaluation**

This section outlines the technical details of the pCODR Economic Guidance Panel's evaluation of the economic evidence that is summarized in the executive summary. In accordance with the *Disclosure of Information Guidelines for the CADTH Pan-Canadian Oncology Drug Review*, this section is not eligible for disclosure. It was provided to the pCODR Expert Review Committee (pERC) for their deliberations and the participating drug programs for their information.

## Appendix 5: Submitted BIA and CADTH Appraisal

This section outlines the technical details of the pCODR Economic Guidance Panel's evaluation of the economic evidence that is summarized in the executive summary. In accordance with the *Disclosure of Information Guidelines for the CADTH Pan-Canadian Oncology Drug Review*, this section is not eligible for disclosure. It was provided to the pCODR Expert Review Committee (pERC) for their deliberations and the participating drug programs for their information.

## References

1. Brigatinib (alunbrig) (*CADTH pCODR initial clinical guidance report*). Ottawa (ON): CADTH; 2021. Unpublished.
2. Camidge R, Kim HR, Ahn MJ, et al. Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: updated results from the phase III ALTA-1L trial [abstract]. *Ann Oncol*. 2019;30(Suppl 9):ix195-ix196.
3. Pharmacoeconomic evaluation. In: pan-Canadian Oncology Drug Review sponsor submission: Alunbrig (brigatinib) for 1st line ALK+ NSCLC, 30 mg, 90 mg, and 180 mg tablets. Takeda Canada Inc. Toronto (ON): Takeda Canada Inc; 2020 Sep 30.
4. Alunbrig (brigatinib): 30 mg, 90 mg, and 180 mg, oral tablets [product monograph]. Toronto (ON): Takeda Canada Inc; 2021 Mar 2.
5. Mok T, Camidge DR, Gadgeel SM, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. *Ann Oncol*. 2020;31(8):1056-1064.
6. Indirect Treatment Comparison Report: brigatinib (Alunbrig) for the first-line treatment of patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) [Internal sponsor's report]. In: pan-Canadian Oncology Drug Review sponsor submission: Alunbrig (brigatinib) for 1st line ALK+ NSCLC, 30 mg, 90 mg, and 180 mg tablets. Takeda Canada Inc. Toronto (ON): Takeda Canada Inc; 2020 Sep 30.
7. Ara R, Brazier JE. Using health state utility values from the general population to approximate baselines in decision analytic models when condition-specific data are not available. *Value Health*. 2011;14(4):539-545.
8. Schedule of benefits for physician services under the Health Insurance Act: effective April 1, 2020. Toronto (ON): Ontario Ministry of Health; 2020: [http://www.health.gov.on.ca/en/pro/programs/ohip/sob/physserv/sob\\_master20200306.pdf](http://www.health.gov.on.ca/en/pro/programs/ohip/sob/physserv/sob_master20200306.pdf). Accessed 2020 Jul 15.
9. Cancer Care Ontario. Funded evidence-informed regimens. 2021; <https://www.cancercareontario.ca/en/drugformulary/regimens>. Accessed 2020 Jun 10.
10. Schedule of benefits for laboratory services: effective July 1, 2020. Toronto (ON): Ontario Ministry of Health; 2020: [http://www.health.gov.on.ca/en/pro/programs/ohip/sob/lab/lab\\_mn2020.pdf](http://www.health.gov.on.ca/en/pro/programs/ohip/sob/lab/lab_mn2020.pdf). Accessed 2020 Jul 15.
11. Government of Canada. Wages for registered nurses and registered psychiatric nurses. 2020; <https://www.jobbank.gc.ca/wagereport/occupation/696>. Accessed 2020 Jun 20.
12. Walker MS, Wong W, Ravelo A, Hazard S, Miller PJ, Schwartzberg L. Impact of disease progression on patient reported outcomes in advanced NSCLC: evidence from patients treated in real world community oncology settings [abstract]. *Value Health*. 2016;19(3):A160.
13. Elliott J, Bai Z, Hsieh SC, et al. ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis. *PLoS One*. 2020;15(2):e0229179.
14. Solomon BJ, Mok T, Kim D-W, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. *N Engl J Med*. 2014;371(23):2167-2177.
15. Delta PA. Ottawa (ON): IQVIA; 2021: <https://www.iqvia.com/>. Accessed 2020 Sep 21.
16. Budget Impact Analysis Report: brigatinib (Alunbrig) for the first-line treatment of patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) [Internal sponsor's report]. In: pan-Canadian Oncology Drug Review sponsor submission: Alunbrig (brigatinib) for 1st line ALK+ NSCLC, 30 mg, 90 mg, and 180 mg tablets. Takeda Canada Inc Toronto (ON): Takeda Canada Inc; 2020 Sep 30.
17. Statistics Canada. Canadian cancer registry (CCR). 2020 <https://www23.statcan.gc.ca/imdb/p2SV.pl?Function=getSurvey&SDDS=3207>. Accessed 2020 Aug 20.
18. Canadian Cancer Statistics Advisory Committee. Canadian cancer statistics: a 2018 special report on cancer incidence by stage. Toronto (ON): Canadian Cancer Society; 2018: <https://www.cancer.ca/~/media/cancer.ca/CW/cancer%20information/cancer%20101/Canadian%20cancer%20statistics/Canadian-Cancer-Statistics-2018-EN.pdf?la=en>. Accessed 2020 Jun 23.
19. Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. *Transl Lung Cancer Res*. 2016;5(3):288-300.
20. Cutz JC, Craddock KJ, Torlakovic E, et al. Canadian anaplastic lymphoma kinase study: a model for multicenter standardization and optimization of ALK testing in lung cancer. *J Thorac Oncol*. 2014;9(9):1255-1263.